Drug reimbursement costs down in Denmark

After a significant increase in 2023, Danish regions' expenses for subsidized medicines fell by 4.3% in 2024.

The decrease is due to factors including increased security of supply, an industry price cap agreement, patent expiries and a reassessment of the reimbursement status of certain medicines, according to Lif, Denmark’s life sciences association.

Pernille Langgaard-Lauridsen, chief consultant, primary sector, Lif, said: “One of the primary reasons for the falling costs is increased security of supply combined with Lif's agreement with the Danish Regions and the Ministry of the Interior and Health on a price cap on pharmacy medicines. In addition, patent expirations that have occurred in 2024 and reassessment of the reimbursement status of several medicines.